SORLA protects mice from tau-related brain damage, study finds

A protein that appears to shield the brain from tau-related damage protected mice from several features associated with Alzheimer’s disease, according to research reported by SciTechDaily. The findings raise the possibility that increasing SORLA could eventually become a treatment strategy for Alzheimer’s and other tauopathies, although the work has so far been conducted in mice.

Researchers at Sanford Burnham Prebys studied what happened when mice produced either unusually high or unusually low amounts of SORLA. Their results, published in Science Advances on 17 July 2026, showed that extra SORLA reduced tau accumulation, brain atrophy and some of the changes linked to impaired cognition. Removing the protein had the opposite effect and made the disease-related damage worse.

Why tau matters in Alzheimer’s disease

Tau has an important normal function. It helps maintain the internal scaffolding of nerve cells by stabilising microscopic structures called microtubules. These structures help preserve the shape and organisation of neurons throughout the brain and nervous system.

The protein becomes harmful when it is altered and gathers into clumps inside nerve cells. These tau tangles are associated with the deterioration and death of neurons, as well as problems with memory and other thinking abilities. A group of diseases characterised by this process is known as tauopathies, with Alzheimer’s disease among the best-known examples.

The Sanford Burnham Prebys team began by crossing mice engineered to make additional human SORLA with mice that develop tau tangles as they age. The disease-model animals normally show shrinking brain tissue and cognitive difficulties. In a separate experiment, the researchers examined mice lacking Sorl1, the gene that provides the instructions for producing SORLA.

That second model also has relevance to people because some individuals carry mutations that disable the same gene. Comparing animals with extra SORLA against those without it allowed the researchers to test whether the protein’s presence was linked to protection, rather than simply being associated with healthier tissue.

Protection extended beyond tau clumps

The experiments indicated that higher SORLA levels interfered with several stages of tau-related injury. They reduced hyperphosphorylation, a chemical modification in which excessive phosphate groups attach to tau. The additional protein also limited tau’s ability to form “seeds” — abnormal pieces that attract more tau and help larger aggregates develop.

The effects were not confined to the tangles themselves. Mice with more SORLA retained more synapses, the contact points that allow neurons to communicate. They also preserved synaptic plasticity, the capacity of those connections to change as the brain processes information and adapts.

The researchers used several molecular methods to investigate how this protection might occur. They measured proteins, examined gene activity and charted the distribution of RNA and proteins in brain tissue. RNA carries instructions that cells use to make proteins, so these analyses provided information about both the molecular machinery and the cells in which it was active.

The results suggested that SORLA prevented disease-associated disruptions in protein production at synapses. It also dampened gene-activity patterns linked with worsening tauopathy in glial cells. Glia support, nourish and protect neurons, meaning the protein’s influence may involve the wider brain environment rather than neurons alone.

A possible route for future treatments

SORLA was already of interest in Alzheimer’s research because previous work has connected it with amyloid beta, the protein that forms another major type of deposit in the disease. According to the researchers, substantial evidence has indicated that SORLA can reduce the production and accumulation of amyloid beta. Its relationship with tau, however, had been much less clear.

The experiments involving SORLA-deficient mice offered another possible lead. The animals showed increased activity in a receptor from the plexin-B family, particularly in the context of glial responses. Because drugs already exist that target this receptor group, the researchers suggested that some might eventually be explored for tau-related dementias.

One proposed approach would be to reduce excessive activation of glial cells and determine whether that could reverse some of the biological changes seen in tauopathies. This remains a research possibility, not an established therapy, and the study does not show that SORLA-boosting medicines are safe or effective in people.

The team plans to examine how different types of human cells respond when SORLA is increased or depleted. Future experiments may place human neurons or glial cells into mouse brains and test the effects of specific SORLA mutations. The researchers say this could provide a closer model of human disease than experiments using mouse cells alone.

The study received support from the National Institutes of Health, the National Cancer Institute and the National Institute on Aging.